ArticleExperimental & molecular medicine2026
MeCP2 regulates cell-type-specific functions of depressive-like symptoms in the nucleus accumbens.
Article in Experimental & molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Methyl-CpG binding protein 2 (MeCP2) is a chromatin-associated transcriptional regulator that modulates neuronal gene programs in response to environmental stimuli. Although MeCP2 has been implicated in stress responses and depression, its cell-type-specific functions within defined limbic circuits remain incompletely understood. Here, using a chronic restraint stress (CRS) model, we show that CRS selectively reduces MeCP2 protein in dopamine D2 receptor (D2R)-expressing medium spiny neurons in the nucleus accumbens (NAc). D2R-restricted MeCP2 knockdown was sufficient to increase immobility in the forced swim test, whereas Cre-dependent restoration of MeCP2 in NAc D2R neurons attenuated CRS-associated behavioral alterations across affective coping, anxiety-like behavior and reward sensitivity. Ex vivo multielectrode array recordings combined with optogenetic stimulation revealed that CRS-associated suppression of NAc activity was normalized toward control levels by MeCP2 restoration. To profile molecular correlates, we performed cell-type-resolved GeoMx digital spatial transcriptomics in virally labeled NAc D2R neurons and found that MeCP2 overexpression was associated with attenuation of CRS-linked transcriptional perturbations, prominently involving synaptic and neuronal communication-related programs. In parallel, we detected CRS-responsive molecular signatures in the ventral pallidum that shifted with NAc D2R-restricted MeCP2 restoration, although these downstream profiles are not projection-resolved. Collectively, our findings identify a D2R neuron-biased role for MeCP2 in the NAc and support the view that restoring MeCP2 in this cell population is associated with mitigation of CRS-induced depression-like phenotypes and accompanying circuit/transcriptomic signatures. Chronic restraint stress (CRS) reduces MeCP2 protein in nucleus accumbens (NAc) D2 receptor (D2R)-expressing neurons, suppressing activity- and synapse-related programs and promoting depressive-like behaviors. Cell-type-specific restoration of MeCP2 in NAc D2R neurons normalizes neuronal activity and attenuates behavioral deficits, accompanied by coordinated transcriptional shifts involving synaptic organization, glutamatergic signaling, potassium channel activity and cytoskeletal regulation. CRS-responsive molecular signatures in the ventral pallidum (VP) show partial normalization in association with MeCP2 upregulation (VP bulk ROIs). Together, these findings implicate MeCP2-dependent regulation of NAc D2R neuron state in stress-related outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.